雷贝拉唑与加替沙星为主的三联疗法根除幽门螺杆菌效果评价  

Efficacy of Triple Therapy Based on Rabeprazole and Gatifloxacin for Eradication of Helicobacter pylori

作　　者：方亮[1] 王昌权[1] 陈颖[1] 吴继雄[1] 

机构地区：[1]湖北省黄冈市中心医院消化内科,湖北黄冈438000

出　　处：《中国药业》2015年第11期97-98,共2页China Pharmaceuticals

摘　　要：目的观察以雷贝拉唑与加替沙星为基础的三联疗法根除幽门螺杆菌(HP)的疗效及不良反应。方法选取2011年2月至2013年3月医院收治的120例HP感染患者,按照随机数字表法分为3组,每组40例,A组给予雷贝拉唑、加替沙星联合甲硝唑治疗,B组给予雷贝拉唑、加替沙星联合阿莫西林治疗,C组给予雷贝拉唑、甲硝唑联合阿莫西林治疗,疗程均为2周,停药4周后复查患者胃镜或14C-尿素呼气试验。结果治疗后3组患者上腹部疼痛、上腹部饱胀、反酸、嗝气症状积分均优于治疗前(P<0.05)。A组临床治疗有效率为97.50%,B组为95.00%,均高于C组的80.00%(P<0.05)。A组、B组患者的HP根除率分别为95.00%和92.50%,均高于C组的75.00%(P<0.05)。结论以雷贝拉唑与加替沙星为基础的三联疗法可有效根除HP,提高疗效,降低不良反应发生率。Objective To investigate the efficacy and adverse reactions of the triple therapy based on rabeprazole and gatifloxacin in the eradication of Helicobacter pylori （HP）. Methods 120 cases of gastritis conforming to HP infection in our hospital from February 2011 to March 2013 were selected and divided into the three groups of A, B and C according to the random number table method, 40 cases in each group. The group A group was given the treatment of rabeprazole, gatifloxacin combined with metronidazole, the group B was given the treatment of rabeprazole, gatifloxacin combined with amoxicillin and the group C was treated with rabeprazole, metronidazole combined with amoxicillin. The course of treatment was 2 weeks. The reexamination of gastroscopy or ^14C- UBT was performed after 4 weeks of drug withdrawal. Results The symptom scores of upper abdominal pain, abdominal fullness, acid regurgitation and belching after treatment in the three groups were better than those before treatment, the differences among 3 groups were statistically significant（P 〈 0. 05）. The effective rate was 97.50% in the group A and 95.00% in the group B, which higher than 80. 00% in the group C（ P 〈 0.05）. The HP eradication rates in the group A and B were 95.00% and 92.50% respectively, which were higher than 75.00% in the group C（ P 〈 O. 05）. Conclusion ：The triple therapy based on rabeprazole and gatifloxacin can effectively eradicate HP, improves the curative efficacy, reduces the incidence rate of adverse reactions, and is worthy of clinical promotion.

关 键 词：雷贝拉唑 加替沙星 三联疗法 幽门螺杆菌 疗效 不良反应 

分 类 号：R969.4[医药卫生—药理学] R975.11[医药卫生—药学]